small_woman.gif (3415 bytes)

 Tamoxifen for early breast cancer: an overview of the randomized trials
Early Breast Cancer Trialists' Collaborative Group     Lancet 1998; 351: 1451 - 146
Benefits of Tamoxifen by Duration of Use
Duration Reduction in Relapse Reduction in Mortality
1y 18% 10%
2y 25% 15%
5y 42% 22%

Benefits of 5y of Tamoxifen based on Receptor Status
Estrogen Receptor Status Reduction in Relapse Reduction in Mortality
ERP - 6% 3% worse
ERP + 50% 28%

Benefits of 5y of Tamoxifen in ERP + by Node Status
Nodes Reduction in Relapse Reduction in Mortality
nodes negative 49% 25%
nodes positive 43% 28%

10 Year Survival by Nodes and Use of Tamoxifen
Nodes Tamoxifen 10y Survival
nodes negative no 73.3%
nodes negative yes 78.9%
nodes positive no 50.5%
nodes positive yes 61.4%

Benefits of Adding Chemotherapy to Tamoxifen in ERP +
Therapy Reduction in Relapse Reduction in Mortality
Tamoxifen 46% 22%
Tamoxifen + Chemotherapy 52% 47%

1

1